On May 11, 2021 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, reported that Dr. William V. Williams, President & CEO of BriaCell, is scheduled to participate in the following virtual conferences (Press release, BriaCell Therapeutics, MAY 11, 2021, View Source [SID1234579657]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
• Benzinga Global Small Cap Investor Conference: May 13-14, 2021
o Dr. Williams will deliver his corporate presentation at 12:20pm ET on May 13, 2021.
o Dr. Williams will also participate in a panel discussion titled "Investing Post COVID – Back to the Fundamentals" at 11:50am ET on May 13, 2021. The panel will discuss healthcare investing in the post COVID world.
o Investors may request one-on-one meetings with Dr. Williams.
o Investors may register for the conference here: View Source
• Q2 Investor Summit: May 17-18, 2021
o Dr. Williams will deliver his corporate presentation at 2:00pm ET on May 17, 2021.
o Investors may request one-on-one meetings with Dr. Williams.
o Investors may register for the conference here: View Source
• 2021 LD Micro Invitational Investor Conference: June 8-10, 2021
o Dr. Williams will deliver his corporate presentation at 12:00pm ET on June 9, 2021.
o Investors may request one-on-one meetings with Dr. Williams.
o Investors may register for the conference here: View Source
• MarketsandMarkets 4th Annual Next Gen Immuno-Oncology Virtual Congress-US Edition: June 28-30, 2021
o Dr. Williams will be speaking at the scientific conference at 11:30am ET on June 29, 2021.
o The topic is "Personalized, off-the-shelf cellular immunotherapy for cancer".
o A copy of the presentation will be posted here: View Source
o For additional information on the conference and the speaker, please visit:
View Source
Separately, BriaCell has recently appointed Miguel A. Lopez-Lago, Ph.D. as Senior Director, Research and Development. Since 2000, Dr. Lopez-Lago has been working as a cancer scientist at Memorial Sloan-Kettering Cancer Center, New York (MSKCC). Specifically, he has investigated various aspects of tumor biology, including the development of targeted therapies for Mesothelioma and the characterization of the biological mechanisms underlying cancer metastasis. More recently, Dr. Lopez-Lago has been interested in the study of the tumor immune-microenvironment and in the development of immunotherapies for thoracic cancers using chimeric antigen receptor (CAR) T cell technologies. Since 2013, Dr. Lopez-Lago has been working as Senior Research Scientist at MSKCC. Dr. Lopez-Lago received his Bachelor of Science in Bio-Sciences and his doctorate in Molecular Biology from Santiago of Compostela University, Spain.